时 间：2024年10月16日上午10:00-11:30
参会地点：国际会议厅（袁家岗校区）
学时分：本次学术报告会授予教职工继续教育2学时，授予研究生每场0.2学分，欢迎广大师生参加！
报告题目：Targeting public neoantigens for cancer immunotherapy:p53R175HandKRASG12V
主讲人：Dr. Sandra Gabelli
Dr. Sandra Gabelli is the Global Head of Protein and Structural Chemistry at the Merck company, one of the leading pharmaceutical companies worldwide. Dr. Gabelli received her PhD degree in Biophysics at the Johns Hopkins University, and wasa tenured faculty of medicine with joint appointments in the departments of Oncology, Biophysics and Biophysical Chemistry, and Art as Applied to Medicine. Dr. Gabelli has published more than 100 research papers, including those in Nature, Science and Cell. Dr. Gabelli’s research is aimed at elucidating the molecular mechanisms of proteins involved in signaling pathways dysregulated in diseases such as cancer. Using structural biology and biochemical approaches, she has made tremendous contribution to the field by elucidating the molecular mechanisms of signal transduction and oncogenic activation in PI3K/AKT/mTOR pathway, the structural basis for novel immunotherapies targeting tumor neoantigens and the detailed molecular features of various pathogen enzymes. Currently, as an academic leader in the Merck company, Dr. Gabelli is passionate to understand the structural basis of signaling in human cancers, cardiovascular diseases, neuroscience and infectious diseases, and facilitate the drug discovery with such structural and molecular understanding.
Sandra Gabelli教授是国际领先药企默克公司的蛋白质与结构化学全球总监。Gabelli教授在约翰霍普金斯大学获得生物物理博士学位，并成为约翰霍普金斯大学肿瘤学系、生物物理学系、医学美术学系的终身教授。Gabelli教授在包括Nature，Science，Cell杂志在内的国际顶级期刊发表超过100篇学术研究论文。她的研究主要是针对在癌症等疾病中异常调控的蛋白质进行分子机理的研究。通过结构生物学和生物化学方法，Gabelli教授的研究成果揭示了PI3K/AKT/mTOR信号通路的传导及异常激活的分子机理，针对肿瘤新抗原的创新免疫疗法的结构基础，以及多种病原生物酶的分子特征等。目前，作为默克公司的学术领军人之一，Gabelli教授致力于癌症、心血管疾病、神经疾病、感染疾病相关的信号通路的结构机制研究，并期望通过这些研究助力新药的研发。
欢迎广大师生参加，请教职工随身携带继续教育登记本/卡，讲座开始前15分钟签到，讲座结束后现场登记。
